Article: GDP - The Critical Link in Maintaining Quality from GMP to the Patient

By Simon Ellison |

Cell and gene therapies are manufactured to good manufacturing practice (GMP) and administered, through clinical trials, under good clinical practice (GCP). To maintain a quality product they should also be transported, globally, under good distribution practice (GDP). To achieve this, World Courier has attained global GDP certification throughout our office network against three major GDP standards, EU GDP, USP 1079 and WHO GDP [1].

1 European Union (EU GDP Guidelines), United States Pharmacopeia (USP 1079) and World Health Organization (WHO GDP).

"The quality of pharmaceutical products can be affected by a lack of adequate control over the numerous activities which occur during the distribution process."

WHO Technical report 937, annex 5, 2006
Process

GDP guidelines regulate the distribution of medicinal products from the manufacturer to the patient. However, transport is generally not covered by national regulatory authorities. The accreditation is therefore awarded by DQS, a leading certification body for management systems worldwide, and is based on a six–month long evaluation process, during which a team of DQS auditors analysed World Courier’s transportation, handling and storage
processes, and tested them against the relevant guidelines.

"Distribution is an important activity in the integrated supply-chain management of pharmaceutical products."

WHO technical report 957, annex 5, 2010
World Courier

World Courier connects therapies to patients. We comply with GxP standards, throughout our 140+ owned office network, have a cell and gene therapy dedicated business unit, and a track record of managing clinical and commercial scale therapies.

Building on successes in supporting cell and gene therapy developers, we have built a logistics platform that enables innovators to quickly utilize the capability of World Courier and distribute life changing therapies.

"The nature of risks involved is likely to be similar to that for risks encountered in the Manufacturing environment."

who technical report 957, annex 5, 2010
Beyond GxP

Our GxP (Good Practice) policy is founded on the established precepts of Good Distribution Practice (GDP), Good Storage Practice (GSP), Good Manufacturing Practice (GMP) and Good Clinical Practice (GCP). GxP is more than a certificate, but a way of thinking and operating. World Courier, therefore, also operates to ICH Q10 – ISO certifications, SOP framework, a comprehensive training system, Overarching Management Review, Continuous Improvement, all supported by a Performance Review Program.

Get in contact

Evolve your supply chain with our global presence

Contact you local World Courier representative today
Contact an Expert

About the Authors

A portrait of Simon Eliison.

Simon Ellison

Cell and Gene Therapy Service Director 
World Courier
Simon is the Cell and Gene Therapy Service Director at World Courier.  His role is to develop a portfolio of global logistic and supporting service strategies that take the advanced therapy industry forwards. Whilst at the Cell and Gene Therapy Catapult he identified the need for, and built the Seamless Freight portfolio.  He also helped develop the commercial operating model for the Catapult Manufacturing Centre that resulted in the first collaborators entering, and the start of a cluster forming around this unique facility. Prior to this Simon was the Head of Commercial at NHS Blood and Transplant (NHSBT) where he merged the needs of the industry with NHSBTs manufacturing and supply chain capability. This enabled multiple UK and international organisations to move their therapies forwards.
View Bio

Michael Fleischer

Director, Quality-Transport
World Courier
View Bio